Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Mar. 31, 2019		22,779,891
Beginning balance at Mar. 31, 2019	$ 56,213	$ 0	$ 741,318	$ (686,016)	$ 911
Increase (Decrease) in Shareholders' Equity (Deficit)
Issuance of shares upon exercise of stock options (in shares)		781
Issuance of shares upon exercise of stock options	5		5
Share-based compensation expense	2,135		2,135
Capital contribution received from Roivant Sciences, Inc.	28		28
Foreign currency translation adjustment	(972)				(972)
Net loss	(28,057)			(28,057)
Ending balance (in shares) at Jun. 30, 2019		22,780,672
Ending balance at Jun. 30, 2019	29,352	$ 0	743,486	(714,073)	(61)
Beginning balance (in shares) at Mar. 31, 2019		22,779,891
Beginning balance at Mar. 31, 2019	56,213	$ 0	741,318	(686,016)	911
Increase (Decrease) in Shareholders' Equity (Deficit)
Net loss	(72,600)
Ending balance (in shares) at Mar. 31, 2020		39,526,299
Ending balance at Mar. 31, 2020	61,558	$ 0	820,257	(758,644)	(55)
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued for restricted stock units (in shares)		53,653
Shares issued for restricted stock units	0
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses of $0.5 million (in shares)		1,393,428
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses of $0.5 million	3,930		3,930
Share-based compensation expense	1,590		1,590
Capital contribution received from Roivant Sciences, Inc.	53		53
Foreign currency translation adjustment	44				44
Net loss	(8,594)			(8,594)
Ending balance (in shares) at Jun. 30, 2020		40,973,380
Ending balance at Jun. 30, 2020	$ 58,581	$ 0	$ 825,830	$ (767,238)	$ (11)